Lobbying activity
Who's lobbying Congress, for whom, and on what, from federal Lobbying Disclosure Act filings. Covers both chambers, synced daily. 95 filings
Top spenders & firms Spend by issue Political contributions Revolving door
Q3
STEALTH BIOTHERAPEUTICS INC. for STEALTH BIOTHERAPEUTICS INC.
Q3
NATIONAL ASSOCIATION OF CHAIN DRUG STORES for NATIONAL ASSOCIATION OF CHAIN DRUG STORES
Q3
BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
Q3
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION for PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Q3
ALZHEIMER'S ASSOCIATION for ALZHEIMER'S ASSOCIATION
Q3
ASSOCIATION FOR CLINICAL ONCOLOGY for ASSOCIATION FOR CLINICAL ONCOLOGY
Q3
ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC) for AMERICAN PHARMACIES, INC.
Q3
PRIME THERAPEUTICS for PRIME THERAPEUTICS
Q3
THE KPM GROUP DC LLC for SOLENO THERAPEUTICS, INC.
1A
AARP for AARP
Q2
SCHOENING STRATEGIES, LLC for AMAC ACTION, INC.
Q2
BANNER PUBLIC AFFAIRS, LLC for THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES)
Q2
AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) for AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
Q2
ALZHEIMER'S ASSOCIATION for ALZHEIMER'S ASSOCIATION
Q2
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
Q2
STEALTH BIOTHERAPEUTICS INC. for STEALTH BIOTHERAPEUTICS INC.
Q2
ELEVANCE HEALTH, INC. for ELEVANCE HEALTH, INC.
Q2
AMERICAN COLLEGE OF RHEUMATOLOGY for AMERICAN COLLEGE OF RHEUMATOLOGY
Q2
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION for PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Q2
BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
Q2
ALBERTSONS COMPANIES, INC. for ALBERTSONS COMPANIES, INC.
Q2
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Q2
NATIONAL ASSOCIATION OF CHAIN DRUG STORES for NATIONAL ASSOCIATION OF CHAIN DRUG STORES
Q2
AMERICAN MEDICAL ASSOCIATION for AMERICAN MEDICAL ASSOCIATION
Q2
ASSOCIATION FOR CLINICAL ONCOLOGY for ASSOCIATION FOR CLINICAL ONCOLOGY